The NIH, FDA and Bill and Melinda Gates Foundation are working with a San Francisco startup whose calling card is an AI-enabled engine that renders patient data unidentifiable by reproducing it in synthetic versions.

Last Tuesday the FDA posted an action plan telling how it will evaluate AI for medical applications going forward. Three days later the agency officially proposed letting numerous products through without review. 

One turnoff is remote food monitoring. Another is real-time feedback—whether from a live healthcare professional or an AI algorithm.

A noted AI researcher and educator who was drawn to the field by its escalating penetration of “the mysteries of perception and cognition” has found a sort of missing link in its evolution. 

The tools could be used by primary care providers to head off adverse respiratory events and suboptimal healthcare utilization. 

An AI application that interprets MRI scans of the brain for signs or confirmation of injury has received 510(k) clearance from the FDA.

After perusing info on AI startups as compiled by Crunchbase, Forbes senior contributor Louis Columbus has named one “to watch” in 2021 that serves exclusively healthcare.

Researchers have found that some AI models do better, on average, than expert psychiatrists at the difficult task.

The FDA’s new Digital Health Center of Excellence has released a document describing how it will henceforth oversee and evaluate software that incorporates AI and machine learning for medical applications.

AI researchers and developers across the U.S. received a powerful if overshadowed shot in the arm on New Year’s Day.

The FDA has cleared UK-based Ultromics to sell an AI-powered tool for diagnosing coronary artery disease (CAD) on echocardiograms.

Gastroenterologists need not fear being replaced by machines—and patients don’t have to worry about robot colonoscopists.